Abstract 2098: CNTF governs exercise-induced myofibroblast reversion in prostate cancer.

Abstract Prostate cancer (PCa) remains a major cause of cancer-related morbidity and mortality in the United States, with more than 2.5 million new cases reported annually. Epidemiological studies suggest that physical exercise reduces PCa risk and progression, yet the underlying molecular and stromal mechanisms remain poorly defined. Here, we demonstrate that long-term and moderate exercise significantly suppresses primary tumor growth and metastatic spread in the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model. Single-cell RNA-seq and spatial analyses of the tumor microenvironment (TME) revealed an abundance of myofibroblast populations in PCa, a hallmark associated with tumor progression and immunosuppression. Exercise robustly reversed this myofibroblast transition, shifting fibroblasts toward a resting phenotype in the TRAMP model. Mechanistically, we identified ciliary neurotrophic factor (CNTF) as an exercise-induced cytokine that restrains myofibroblast transition and enhances CD8+ T-cell infiltration within the TME. This CNTF-dependent remodeling of the TME emerged as a key determinant of the anti-tumor effects of exercise. Therapeutically, recombinant CNTF suppressed PCa tumor growth in vivo and demonstrated synergy with immune checkpoint blockade, suggesting that CNTF restoration provides a promising strategy to sensitize PCa to immunotherapy. Collectively, our findings reveal a previously unrecognized CNTF-mediated axis that links physical exercise to fibroblast plasticity and anti-tumor immunity in PCa. This work also provides critical insights into mitigating potential risk factors for PCa patient survival outcomes, offering an avenue for further studies that may serve as a foundation for future clinical considerations for patients with this cancer type. Citation Format: Pengju Gong, Yuan Liu, Leng Han, Liuqing Yang, Chunru Lin. CNTF governs exercise-induced myofibroblast reversion in prostate cancer abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2098.